Regenerative Medical Technology Group Inc. (RMTG) stock
Close on Oct 19, 2026Market cap $497.25KP/E –Yield –
Regenerative Medical Technology Group Inc. grew revenue 94.3% to $9.41M over the twelve months to Jun 30, 2026. Operating income fell 84.7% to $43.73K, moving the operating margin from 5.9% to 0.5%. Free cash flow was -$582.33K. At the latest close the market valued the company at $497.25K.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $497.25K
- P/E ratio
- –
- Price to sales
- 0.05
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -117.11%
Fundamentals
- Revenue
- $9.41M
- Net income
- -$9.53M
- EPS, diluted
- -$0.75
- Free cash flow
- -$582.33K
- Book value per share
- -$2.97
- Diluted shares
- 13M
Trading
- Previous close
- $0.04
- Open
- $0.04
- Day's range
- $0.04 – $0.04
- Volume
- 33,318
- Average volume (20 days)
- 47,923
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | RMTG | S&P 500 | Difference | RMTG per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -52.5% | +0.6% | −53.1 pts | ||
| 3 months | -57.8% | +3.4% | −61.1 pts | ||
| Year to date | -23.3% | +13.3% | −36.5 pts | ||
| 1 year | -31.6% | +16.6% | −48.2 pts | ||
| 3 years | +191.5% | +86.4% | +105.1 pts | +42.8% | +23.1% |
| 5 years | -65.6% | +81.9% | −147.5 pts | -19.2% | +12.7% |
| 10 years | -87.5% | +318.9% | −406.3 pts | -18.8% | +15.4% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Regenerative Medical Technology filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- Results
- Results
- News
- News
About Regenerative Medical Technology
Retail-Retail Stores, NEC
Regenerative Medical Technology Group Inc. operates as a vertically integrated provider in the regenerative medicine industry through its subsidiary, Global Stem Cells Group. The company develops, manufactures, and distributes biologics and therapeutics, including exosomes, mesenchymal stem cells, and peptide products under the Cellgenic brand. In addition to manufacturing consumables and clinical equipment, it offers professional medical training, certifications, and educational events via the International Society for Stem Cell Applications. The business also provides clinical treatments and digital healthcare software platforms, serving physicians, medical providers, affiliated clinics, and patients seeking regenerative and longevity therapies.
Company profile, executives and historyRegenerative Medical Technology stock: common questions
What is Regenerative Medical Technology's stock price?
RMTG closed at $0.04 on Oct 19, 2026, down 5.76% on the day.
What is Regenerative Medical Technology's market cap?
Regenerative Medical Technology was worth $497.25K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is RMTG's P/E ratio?
Regenerative Medical Technology lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.75), so it has no meaningful P/E ratio.
How much revenue does Regenerative Medical Technology make?
Regenerative Medical Technology reported revenue of $9.41M for the twelve months to Jun 30, 2026, up 94.3% from a year earlier.
Does Regenerative Medical Technology pay a dividend?
No. Regenerative Medical Technology has not paid a cash dividend over the last twelve months.
How has RMTG stock performed over the past year?
Including dividends, RMTG returned -31.6% over the past year, against +16.6% for the S&P 500.
Who are Regenerative Medical Technology's competitors?
Companies most similar to Regenerative Medical Technology by business, industry and size include INHD, RCT, ISCO, ZEOX, WOK.
See a number that looks wrong?